1016 GMT - Novartis's raised guidance reflects its solid sales performance, Intron Health analysts say in a note. Meanwhile, the Swiss drugmaker benefited from some U.S. revenue deduction adjustments, the analysts say. Its breast cancer drug Kisqali, blood-disorder treatment Fabhalta and leukemia treatment Scemblix beat consensus estimates, while eye drug Lucentis missed views. Its key growth drivers--heart drug Entresto and psoriasis treatment Cosentyx--were in line with expectations, they add. Shares are up 0.95% at 94.28 euros. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 29, 2025 06:16 ET (10:16 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.